|
Study of ABT-751 in Patients with Refractory Hematologic Malignancies Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Study of ABT-751 in Patients with Refractory Hematologic Malignancies conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of ABT-751 in Patients with Refractory Hematologic Malignancies Clinical research trials and Study of ABT-751 in Patients with Refractory Hematologic Malignancies medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Study of ABT-751 in Patients with Refractory Hematologic Malignancies. Study of ABT-751 in Patients with Refractory Hematologic Malignancies Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Study of ABT-751 in Patients with Refractory Hematologic Malignancies clinical trial. Participants oftentimes recieve the finest healthcare available for their Study of ABT-751 in Patients with Refractory Hematologic Malignancies condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of ABT-751 in Patients with Refractory Hematologic Malignancies  Study of ABT-751 in Patients with Refractory Hematologic Malignancies
Study of ABT-751 in Patients with Refractory Hematologic Malignancies
For Condition: Hematological Malignancies
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.
Details: The current low cure rates in most patients with advanced hematologic cancers indicate the need to identify new agents that can be incorporated with current therapies to improve prognosis. The vinca alkaloids are effective broad-spectrum anti-leukemic drugs. Microtubules are a major structural component of cells. They play a role in cell shape, cellular polarity, cellular movement, intracellular transport and the segregation of chromosomes during mitosis. The cellular microtubule dynamics are highly regulated. As cells enter mitosis, the interphase microtubules disappear and are replaced with a new network of microtubules that interact with the mitotic spindle. Disruption of these new microtubules leads to cell cycle arrest. These important and highly labile microtubule arrays comprising the mitotic spindle are the principal target of oncologic antimitotic compounds. Known antimitotic agents fall into three classes, the vinca alkaloids (vincristine, vinblastine, and vinorelbine), taxanes (paclitaxel and docetaxel), and colchicine-site binders. There are no colchicine-site agents currently approved for cancer chemotherapy. These three classes of compounds have distinct binding sites on the tubulin subunits. ABT-751 is a novel orally administered antimitotic agent that binds to the colchicine site on beta-tubulin and inhibits polymerization of microtubules.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 17 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Patients with relapsed or refractory acute leukemias (AML, ALL, MDS [RAEB, RAEBT], CMML in transformation with >/= 10% peripheral blood/bone marrow blasts, CML in blast crisis), and patients with relapsed/refractory or transformed CLL. - Signed informed consent indicating that patients are aware of the investigational nature of this study, and in keeping with the policies of this hospital. - ECOG performance status 16 years - a separate Phase I study is being conducted in the pediatric population. Exclusion Criteria - Any severe, concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for study entry. - Pregnant and/or lactating females. - Those with documented sulfonamide allergy should be excluded from study participation.
Total Enrollment: 40
Location and Contact Information:
The University of Texas M.D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Francis Giles 713-792-8217
Additional Information:
Study ID Numbers: DM01-646;
Study Start Date: December 2002
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047489
Other Hematological Malignancies Studies:
1. Study of ABT-751 in Patients with Refractory Hematologic Malignancies
Related Studies:
Other Hematological Malignancies Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Study of ABT-751 in Patients with Refractory Hematologic Malignancies
|
|
|
|
|
|
|
|
